Poor tracking provokes consent decree at Telectronics:
This article was originally published in Clinica
Executive Summary
Ineffective tracking by Telectronics (US) has prompted the FDA to block sales and manufacture of leads. The troubled pacemaker company cannot resume operations until a proper system for monitoring the safety of its implantable pacemaker products has been approved by an external auditor. The FDA consent decree follows warning letters sent to the company last October. It does not affect exports or leads already shipped to distributors.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.